Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Locally Advanced, Irresectable dMMR Colorectal Cancer
NCT05131919Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2022
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoint: Objective Response Rate at 2.5 years. Started Dec 2022; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05131919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131919.